{
  "label": "clinical_signal_03_dx_vaccine_immunogenicity_013",
  "artifact_type": "distractor_episode",
  "artifact_id": "sha256:edb71833e90ebcf9c3d30dc944817323689f2c61706894268af12b58480f1810",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:b9a5f4498416bfb2148e106e9d25ca838481bb56025a18e16baf31718f4ee4a2"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:00:39.575074",
  "content": "## 2024-05-27 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 105\n- Active: 100\n- Screen Failures Cumulative: 17\n- Withdrawals Cumulative: 5\n\n#### By Dose Group\n- Low Dose: 24\n- Mid Dose: 25\n- High Dose: 29\n- Placebo: 27\n\n### Immunogenicity By Group\n\n#### Low Dose\n- IgG Titer (GMU) Mean: 77.9\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 19.3\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 126.3\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC/10^6) Mean: 196.0\n- CD4 Response (SFC/10^6) SD: 15.0\n- CD8 Response (SFC/10^6) Mean: 131.0\n- CD8 Response (SFC/10^6) SD: 11.0\n- Seroconversion Percentage: 27.9\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 123.6\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 27.4\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 197.1\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC/10^6) Mean: 306.0\n- CD4 Response (SFC/10^6) SD: 24.0\n- CD8 Response (SFC/10^6) Mean: 210.0\n- CD8 Response (SFC/10^6) SD: 18.0\n- Seroconversion Percentage: 52.0\n\n#### High Dose\n- IgG Titer (GMU) Mean: 172.1\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 41.1\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 274.0\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC/10^6) Mean: 414.0\n- CD4 Response (SFC/10^6) SD: 33.0\n- CD8 Response (SFC/10^6) Mean: 285.0\n- CD8 Response (SFC/10^6) SD: 24.0\n- Seroconversion Percentage: 71.1\n\n#### Placebo\n- IgG Titer (GMU) Mean: 20.5\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 5.6\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 25.3\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC/10^6) Mean: 45.0\n- CD4 Response (SFC/10^6) SD: 3.0\n- CD8 Response (SFC/10^6) Mean: 22.0\n- CD8 Response (SFC/10^6) SD: 2.0\n- Seroconversion Percentage: 9.5\n\n### Injection Site Reactions\n- Pain Percentage: 35.6\n- Erythema Percentage: 23.6\n- Swelling Percentage: 6.5\n- Induration Percentage: 9.7\n- Mean Pain Duration (Hours): 16.6\n\n### Systemic Reactogenicity\n- Fever Percentage: 11.5\n- Fatigue Percentage: 24.5\n- Myalgia Percentage: 24.0\n- Headache Percentage: 17.8\n- Chills Percentage: 8.6\n\n### Safety Labs\n- WBC (K) Mean: 5.8\n- WBC (K) SD: 1.0\n- Lymphocyte Percentage Mean: 34.7\n- Lymphocyte Percentage SD: 7.3\n- Neutrophil Percentage Mean: 57.5\n- Neutrophil Percentage SD: 6.0\n- Platelets (K) Mean: 226\n- Platelets (K) SD: 41\n- CRP (mg/L) Mean: 5.1\n- CRP (mg/L) SD: 2.0\n- Hemoglobin (g/dL) Mean: 13.1\n- Hemoglobin (g/dL) SD: 1.2\n\n### Adverse Events\n- AE ID: VI-AE-1328, Description: nausea, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1347, Description: lymphadenopathy, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1306, Description: malaise, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1326, Description: fever, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n\n### Events\n- DSMB safety review teleconference completed\n- Immunology core lab QC report received\n\n### Notes\n- Week 13: Immunogenicity assessments on schedule. 105 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
  "metadata": {
    "episode_type": "distractor",
    "theme": "vaccine_immunogenicity",
    "theme_index": 1,
    "local_index": 13,
    "scope_id": "clinical_signal_03",
    "layer_name": "distractor_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "86d399f4ea18a5663d6624e24cd8b639bcd4c45932ccbdc83c5254419dc5a8df",
      "components": {
        "transform": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
        "inputs": "c06ced136368edaf"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
      "components": {
        "transform_id": "01137a4997b78f86",
        "source": "c42d9c6282d5331f",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}